- 作者：Irene M. Lips ; M.D.&lowast ; ; i.m.lips@umcutrecht.nl ; Carla H. van Gils ; Ph.D.&dagger ; ; Alexis N.T.J. Kotte ; Ph.D.&lowast ; ; Monique E. van Leerdam ; M.D. ; Ph.D.&Dagger ; ; Stefan P.G. Franken ; M.D.&lowast ; ; Uulke A. van der Heide ; Ph.D.&lowast ; ; Marco van Vulpen ; M.D. ; Ph.D.&lowast ;
- 关键词：Prostate cancer ; Intrafraction motion ; Intensity-modulated radiation therapy ; Magnesium oxide ; Randomized trial
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2012
- 期刊代码：136_03603016
- 类别：med
- 出版时间：1 June, 2012
- 卷：83
- 期：2
- 页码：653-660
- 文件大小：491 K
At the Department of Radiotherapy, prostate cancer patients scheduled for intensity-modulated radiotherapy (77 Gy in 35 fractions) using fiducial marker-based position verification were randomly assigned to receive magnesium oxide (500 mg twice a day) or placebo during radiotherapy. The primary outcome was the proportion of patients with clinically relevant intrafraction prostate motion, defined as the proportion of patients who demonstrated in 鈮?0%of the fractions an intrafraction motion outside a range of 2 mm. Secondary outcome measures included quality of life and acute toxicity.<h4 class="h4">Resultsh4>
In total, 46 patients per treatment arm were enrolled. The primary endpoint did not show a statistically significant difference between the treatment arms with a percentage of patients with clinically relevant intrafraction motion of 83%in the magnesium oxide arm as compared with 80%in the placebo arm (p = 1.00). Concerning the secondary endpoints, exploratory analyses demonstrated a trend towards worsened quality of life and slightly more toxicity in the magnesium oxide arm than in the placebo arm; however, these differences were not statistically significant.<h4 class="h4">Conclusionsh4>
Magnesium oxide is not effective in reducing the intrafraction prostate motion during external-beam radiotherapy, and therefore there is no indication to use it in clinical practice for this purpose.